3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Glioblastoma
1
Genomic Instability
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma of Lung
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
ALK Gene Rearrangement Positive
1
Interventions
Carboplatin
171
Paclitaxel
129
Radiotherapy
119
Cisplatin
109
Docetaxel
93
Gemcitabine
81
Erlotinib Hydrochloride
80
Pemetrexed
78
Bevacizumab
56
Etoposide
41
pembrolizumab
36
Gefitinib
32
Vinorelbine
31
Topotecan
30
Surveys and Questionnaires
29
Irinotecan
28
Radiosurgery
21
Nivolumab
20
Drug Therapy
20
Magnetic Resonance Spectroscopy
18
Cetuximab
18
durvalumab
17
Early Intervention, Educational
17
Blood Specimen Collection
17
Surgical Procedures, Operative
16
Cyclophosphamide
16
Celecoxib
15
Ipilimumab
14
Immunohistochemistry
14
Filgrastim
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lung Neoplasms
×
alectinib
×
Clear all
NCT05081674
2023-10-11
BLISS
Hospital Israelita Albert Einstein
Phase 2
Completed
154 enrolled